Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose daptomycin in ICU patients with severe Gram-positive infections
ChiCTR2100041991Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Jul 2020
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of daptomycin in Gram-positive bacterial infection, Staphylococcus aureus infection, Staphylococcus epidermidis infection and 7 more (2 arms), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoints: Percentage of successful clinical treatment, Incidence of acute adverse events and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
daptomycin
03
Conditions
Gram-positive bacterial infectionStaphylococcus aureus infectionStaphylococcus epidermidis infectionenterococcal infectionbloodstream infection (BSI)
Beyond the preview
Go deeper on ChiCTR2100041991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041991.